Three RFPs Now Open for Qualified Researchers through NORD’s Jayne Holtzer Rare Disease Research Grants Program
April 29, 2022, Washington, DC – Today, the National Organization for Rare Disorders (NORD®) announced three new requests for proposal (RFP) for grant funding related to the following rare diseases: Autoimmune Polyglandular Syndrome Type 1 (APS-1), Levy-Yeboa Syndrome (LYS), and Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS). The NORD Jayne Holtzer Rare Disease Research Grants Program provides seed-money grants to qualified investigators for scientific and clinical research. NORD’s program provides grants for the study of diseases for which there are few other sources of funding.
- With funding from the APS Type 1 Foundation, NORD is accepting applications for one grant of $50,000 for scientific and/or clinical research studies related to APS-1. Deadline for letters of intent is Tuesday, June 21. More information and to apply.
- With fundraising by the Maxwell Family, NORD is accepting applications for one grant up to $40,000 for scientific and/or clinical research studies related to LYS. Deadline for letters of intent is Tuesday, June 21. More information and to apply.
- With funding from the MMIHS Foundation, NORD is accepting applications for one grant of $30,000 for scientific and/or clinical research studies related to MMIHS . Deadline for letters of intent is Tuesday, June 21. More information and to apply.
Grants will be awarded to qualified researchers to initiate small scientific research studies or clinical trials, the results of which could be used to obtain funding from the National Institutes for Health (NIH), US Food and Drug Administration (FDA), or other funding agencies, or to attract a corporate sponsor.
“Since 1989, NORD’s grants have led to the development of two FDA-approved treatments and many peer-reviewed publications. Over 200 grants have been awarded, totaling over $9 million in approved funding. The vision behind these critical study grants is to ultimately lead to new diagnostics, treatments, and cures for rare diseases,” said Aliza Fink, Director, Research Programs, NORD.
To learn more or submit to the 2022 NORD Research Grants Cycle, visit the NORD website.
About the National Organization for Rare Disorders (NORD)
The National Organization for Rare Disorders (NORD) is the leading independent advocacy organization representing all patients and families affected by rare diseases in the United States. NORD began as a small group of patient advocates that formed a coalition to unify and mobilize support to pass the Orphan Drug Act of 1983. Since then, the organization has led the way in voicing the needs of the rare disease community, driving supportive policies, furthering education, advancing medical research, and providing patient and family services for those who need them most. Together with over 300 disease-specific member organizations, more than 17,000 Rare Action Network advocates across all 50 states, and national and global partners, NORD delivers on its mission to improve the lives of those impacted by rare diseases. Visit rarediseases.org.